AML

Astellas Xospata comes up short again in bid to expand leukemia use
Astellas Xospata comes up short again in bid to expand leukemia use
Fierce Pharma
Astellas
Xospata
AML
clinical trials
Flag link:
Patient death spurs trial halt for Magenta Therapeutics
Patient death spurs trial halt for Magenta Therapeutics
Endpoints
Magenta Therapeutics
MGTA-117
clinical trials
patient deaths
AML
myelodysplastic syndrome
Flag link:
Priothera begins subject enrolment in AML therapy trial
Priothera begins subject enrolment in AML therapy trial
Clinical Trials Arena
Priothera
AML
mocravimod
Flag link:
Roche offers up to $554M in biobucks to in-need Kronos for small-molecule discovery pact
Roche offers up to $554M in biobucks to in-need Kronos for small-molecule discovery pact
Fierce Biotech
Kronos Bio
biobucks
AML
Roche
Genentech
small molecule drugs
drug discovery
Flag link:
Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50%
Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50%
Pulse 2.0
Magenta Therapeutics
clinical trials
MGTA-117
AML
myelodysplastic syndrome
Flag link:
Rigel’s Rezlidhia (olutasidenib) Gets FDA Approval for Relapsed or Refractory AML
Rigel’s Rezlidhia (olutasidenib) Gets FDA Approval for Relapsed or Refractory AML
Xtalks
Rigel Pharmaceuticals
Rezlidhia
olutasidenib
FDA
AML
Flag link:
After nearly 20 years, Cyclacel kicks phase 3 leukemia drug back to Daiichi
After nearly 20 years, Cyclacel kicks phase 3 leukemia drug back to Daiichi
Fierce Biotech
Cyclacel
AML
Sapacitabine
Daiichi Sankyo
Flag link:
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS
BioSpace
Foghorn Therapeutics
FHD-286
AML
MDS
FDA
clinical trials
Flag link:
FDA grants fast track designation for Priothera’s AML therapy
FDA grants fast track designation for Priothera’s AML therapy
Pharmaceutical Business Review
Priothera
mocravimod
stem cells
AML
Flag link:
FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial
FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial
Benzinga
Foghorn Therapeutics
clinical trials
FDA
FHD-286
acute myelogenous leukemia
AML
patient death
Flag link:
Gilead's CD47 clinical hold expands as CEO O'Day expresses 'sense of urgency' in getting trials back on track
Gilead's CD47 clinical hold expands as CEO O'Day expresses 'sense of urgency' in getting trials back on track
Fierce Biotech
Gilead Sciences
clinical trials
clinical hold
magrolimab
AML
MDS
Flag link:
MaaT wraps up cancer microbiome trial early to power into phase 2/3 this year
MaaT wraps up cancer microbiome trial early to power into phase 2/3 this year
Fierce Biotech
MaaT Pharma
microbiome
clinical trials
AML
Flag link:
ASH: Servier's Tibsovo triumph in leukemia study primes med for combo use—and possibly Europe
ASH: Servier's Tibsovo triumph in leukemia study primes med for combo use—and possibly Europe
Fierce Pharma
ASH2021
Servier
Tibsovo
AML
Flag link:
ASH: Senti Bio's gene circuit CAR-NK cell therapy enhances cancer killing and safety in leukemia models
ASH: Senti Bio's gene circuit CAR-NK cell therapy enhances cancer killing and safety in leukemia models
Fierce Biotech
Senti Biosciences
natural killer cells
AML
CAR-NK
Flag link:
What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More
What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More
OBR Oncology
ASH2021
CAR-T
lymphoma
Yescarta
Tibsovo
blood cancers
COVID-19
AML
Flag link:
Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
BioSpace
Kura Oncology
KOMET-001
KO-539
AML
patient deaths
Flag link:
Aptevo Soars on Reports of Complete Remission in AML
Aptevo Soars on Reports of Complete Remission in AML
BioSpace
Aptevo
clinical trials
AML
APVO436
bispecifics
Flag link:
Rafael resets after phase 3 flop, parting ways with 5 execs and reinstating telecom tycoon as CEO
Rafael resets after phase 3 flop, parting ways with 5 execs and reinstating telecom tycoon as CEO
Fierce Biotech
Rafael Pharmaceuticals
devimistat
clinical trials
pancreatic cancer
AML
reorganization
Flag link:
Daiichi could be rewarded for persisting with Vanflyta
Daiichi could be rewarded for persisting with Vanflyta
EP Vantage
Daiichi Sankyo
Vanflyta
AML
Flag link:
FDA slaps clinical hold on AstraZeneca cancer drug amid heart safety scare in combo test
FDA slaps clinical hold on AstraZeneca cancer drug amid heart safety scare in combo test
Fierce Biotech
AstraZeneca
clinical trials
FDA
clinical hold
AZD5991
AML
Flag link:

Pages